Sandoz Aktie

61,68 EUR -0,34 EUR -0,55 %

07:30:24

BMN

57,96 CHF +0,24 CHF +0,42 %

15.12.2025

BRX

Sandoz jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Div. Rendite1,61%

WKNSANDOZ

ISINCH1243598427

SymbolSDZXF

Sandoz Aktien News

Sortieren:Datum Meistgelesen

08.12.25EQS GroupSandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership

01.12.25EQS GroupSandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients

24.11.25EQS GroupSandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases

WerbungSandoz-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

17.11.25EQS GroupSandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar

12.11.25EQS GroupSandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab

04.11.25EQS GroupSandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse

30.10.25EQS GroupSandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded

09.09.25EQS GroupSandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar

28.08.25EQS GroupSandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options

02.06.25GlobeNewswireSandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

21.05.25GlobeNewswireSandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

30.04.25GlobeNewswireSandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

29.04.25GlobeNewswireSandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

15.04.25GlobeNewswireShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

14.04.25GlobeNewswire[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

14.04.25GlobeNewswireSandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

31.03.25GlobeNewswireSandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

05.03.25GlobeNewswireSandoz reports strong FY 2024 results and Q4 2024 sales

24.02.25GlobeNewswireSandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

03.02.25GlobeNewswireFrancisco Ballester to retire; Peter Stenico appointed President Region International

14.01.25GlobeNewswireSandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

17.12.24GlobeNewswireSandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

15.11.24GlobeNewswireSandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

30.10.24GlobeNewswireSandoz reports third-quarter and nine-month 2024 sales

12.08.24GlobeNewswireSandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

08.08.24GlobeNewswireSandoz reports second-quarter sales and half-year 2024 results

25.07.24GlobeNewswireSandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

01.07.24GlobeNewswireFDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

22.05.24GlobeNewswireSandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

07.05.24GlobeNewswireSandoz reports first quarter 2024 sales

30.04.24GlobeNewswireShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

30.04.24GlobeNewswireSandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

22.04.24GlobeNewswireSandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

21.03.24GlobeNewswireSandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

05.03.24GlobeNewswireSandoz receives FDA approval for first and only denosumab biosimilars

05.03.24GlobeNewswireSandoz announces nominations to the Board of Directors and leadership change

04.03.24GlobeNewswireSandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

29.02.24GlobeNewswireSandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs

01.02.24GlobeNewswireSandoz announces changes in the Board of Directors

31.01.24GlobeNewswireSandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz News

Sandoz News: auf dieser Seite finden Sie alle Sandoz News und Nachrichten zur Sandoz Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sandoz News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sandoz News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.